GTx, Inc. (NASDAQ:GTXI)
A biopharmaceutical company dedicated to the discovery, development & commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis & bone loss, muscle wasting & other serious medical conditions.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
MajorBob04
(74.60)
Submitted: 2/6/2012 3:57:34 PM :
Start Price:
$6.14
GTXI Score:
+3.71
Short-term who knows where this one is going. Long-term, there does not appear to be anything to support the high valuation of this company.
Recs
Momentum21
(97.03)
Submitted: 1/30/2012 1:45:30 PM :
Start Price:
$5.71
GTXI Score:
-0.70
thank God I am not trying this play in real life...
Recs
zzlangerhans
(99.23)
Submitted: 1/30/2012 1:35:50 PM :
Start Price:
$5.13
GTXI Score:
-12.34
Nice. By the time I get around to writing the pitch I'm already down 10%. Thanks CAPS for giving me the share price half an hour before I put my pick in. Anyway, GTx is up 50% at this point because Citigroup analysts decided it was worth $19 per share. In reality, the opinion of Citigroup analysts has little to do with the true value of the stock, although it is unpredictable to what degree and for how long their upgrade will affect the share price.
GTx was flying high in 2007 and 2008 on optimism for their SERM prostate cancer drug toremifene, which now appears to have flamed out completely after mixed data and an FDA rejection in 2009. SARM Ostarine for cancer cachexia and muscle wasting is in phase III trials but this appears to be a limited commercial opportunity. The recovery from recent lows of 2.36 appears to rest on the shoulders of oral estrogen alpha receptor agonist Capesaris, now in phase II trials for prostate cancer. Nothing much has recently changed regarding those trials, and I think Capesaris is way too preliminary to justify a 300M enterprise value even with Ostarine thrown in.
Analysts at major banks care little about the accuracy of their price targets, as they are never held accountable by the street. Upgrades such as this are frequently released to curry favor with the company and garner lucrative future business, such as the secondary offering that I think is likely to follow after a respectable interval. With 4.6M in recent buying by GTx Director Joseph Hyde, I'm sure Citibank has made at least one influential friend on the inside.
Recs
bluetune1
(52.25)
Submitted: 10/19/2011 12:52:38 AM :
Start Price:
$4.24
GTXI Score:
+29.73
Developer of anti-cancer drugs. Insiders have been buying in a frenzy....are they right?
Recs
Recs
ipsiety
(26.63)
Submitted: 7/3/2011 2:10:04 AM :
Start Price:
$4.73
GTXI Score:
+24.62
inisder bought 4.6m worth of shares at 4.75 each. cash rich, zero debt.
Recs
k0stid0g004
(< 20)
Submitted: 3/17/2011 10:15:32 AM :
Start Price:
$2.31
GTXI Score:
+151.68
Jan 1 ..Six different directors purchased shares on the open market at $2.65. Seems like confidence. Pure speculation though.
Recs
AndrewGreenBull
(98.78)
Submitted: 2/11/2010 11:12:21 AM :
Start Price:
$4.01
GTXI Score:
+24.26
the company will be back like SOMX soon
Recs
FJW1000000
(85.83)
Submitted: 11/5/2009 1:28:52 PM :
Start Price:
$3.81
GTXI Score:
+29.09
Company just took a big undesetrved hit. Current drugs are strong and good market share. Figure speculators took a bath on FDA issue and dumped all shares at any price. GTXI is cheap today
Recs
TraderHater
(< 20)
Submitted: 11/3/2009 4:55:22 PM :
Start Price:
$3.90
GTXI Score:
-24.30
These guys are toast
Recs
Popnfresh100
(93.77)
Submitted: 11/2/2009 12:46:40 PM :
Start Price:
$4.88
GTXI Score:
-8.77
Glimmers of hope- meeting with the FDA to discuss future rulings, drug has technically not been rejected.
Recs
ranchclub
(< 20)
Submitted: 9/23/2009 12:59:29 PM :
Start Price:
$13.03
GTXI Score:
+80.31
Pharma company with cancer trials. I bet against curing cancer even though that would be great.
Recs
becon800
(99.78)
Submitted: 2/6/2009 3:34:46 PM :
Start Price:
$11.33
GTXI Score:
-105.29
Decision from the FDA by 2/28/08. It would be the first approval of its kind so the stock should rally.
Recs
biovestor
(< 20)
Submitted: 6/28/2008 6:29:53 AM :
Start Price:
$14.63
GTXI Score:
-68.33
Promisng treatment for prostate cancer in late-stage development likely to fuel gains for GTXI over the next year or so.
Recs
crl2007
(69.70)
Submitted: 5/29/2008 10:29:12 AM :
Start Price:
$15.40
GTXI Score:
-61.67
s+p strong buy, reuters rated out-perform, target price $27
Recs
johnearl12
(< 20)
Submitted: 5/4/2008 9:09:18 PM :
Start Price:
$18.21
GTXI Score:
-66.68
It has a couple of Phase lll trials going on. It is about ready to pop. Great short term possibilities and great long term too. It has good buzz in the market place. Several reports state it will have unbelievable growth when the products hit the market soon.
Recs
DANSEVILLE
(< 20)
Submitted: 4/10/2008 9:33:25 PM :
Start Price:
$15.50
GTXI Score:
-65.54
THERE ARE SEVERAL OPTIONS ON THE TABLE NOW. THERE WILL BE AN ANNOUCEMENT APRIL 12-15 CONCERNING THE FINAL TRAILS OF THEIR DRUGS
Recs
marinalee
(< 20)
Submitted: 8/22/2007 5:32:09 AM :
Start Price:
$18.49
GTXI Score:
-65.25
ready for the gate
Recs
sogreek
(< 20)
Submitted: 7/24/2007 4:38:26 PM :
Start Price:
$14.96
GTXI Score:
-53.82
has taken a beatin lately...but I am still in love with the pipeline.
Recs
iceman7403
(44.94)
Submitted: 5/7/2007 5:50:39 PM :
Start Price:
$19.82
GTXI Score:
-64.86
great pipeline and collaborations with large pharmas
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 23 : 1 2 Next »